Valuation: BioRestorative Therapies, Inc.

Market Cap 5.2M 4.5M 4.2M 3.85M 7.25M 495M 7.36M 49.17M 19.31M 248M 19.51M 19.09M 820M P/E 2026 *
-0.41x
P/E 2027 * -0.5x
Enterprise Value 5.2M 4.5M 4.2M 3.85M 7.25M 495M 7.36M 49.17M 19.31M 248M 19.51M 19.09M 820M EV / Sales 2026 *
3.7x
EV / Sales 2027 * 2.25x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 32 13/07/2026
Investor Relations Contact - -
Corporate Officer/Principal - 22/10/2025
Director TitleAgeSince
Director/Board Member 28 12/06/2026
Director/Board Member 37 12/06/2026
Director/Board Member - 13/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+0.25% - - 5.2M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.57%+11.68%+54.00%+207.62% 29.28B
Weighted average by Cap. +4.36%+13.10%+50.69%+168.47%

Financials

2026 *2027 *
Net sales 1.4M 1.22M 1.14M 1.04M 1.96M 134M 1.99M 13.29M 5.22M 66.97M 5.28M 5.16M 222M 2.31M 2M 1.87M 1.71M 3.22M 220M 3.27M 21.88M 8.59M 110M 8.68M 8.49M 365M
Net income -13.52M -11.7M -10.93M -10.02M -18.86M -1.29B -19.14M -128M -50.24M -645M -50.77M -49.67M -2.13B -15.56M -13.46M -12.58M -11.53M -21.69M -1.48B -22.02M -147M -57.8M -742M -58.41M -57.14M -2.46B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-